Molecular Biomarker Testing in Kidney Cancer: Integrating Diagnosis, Prediction, and Emerging Renal Tumor Entities
Abstract
Simple Summary Kidney tumors include many distinct entities that may appear similar under the microscope but differ in their molecular features, clinical behavior, hereditary implications, and response to treatment. This review explains how molecular biomarkers can be integrated with routine microscopic examination and immunohistochemistry to improve tumor classification, identify newly recognized and hereditary renal tumor types, and support prognosis and treatment selection. It also highlights the practical limitations of current testing and discusses emerging approaches, including methylation profiling, transcriptomic classifiers, liquid biopsy, and artificial intelligence.